Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.58 |
| ▸ | EGFR | P00533 | 6/20 | 0.48 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374267 | 0.87 | LCK (0.76) | LCKEGFRFGFR1CYP3A4FGFR3 | |
| SCHEMBL374072 | 0.77 | LCK (0.62) | LCKEGFRFGFR1CYP3A4FGFR3 | |
| SCHEMBL374719 | 0.77 | LCK (0.73) | LCKCYP3A4FGFR3CYP2C19 | |
| SCHEMBL379004 | 0.76 | EGFR (0.69) | LCKEGFRERBB3FGFR1FGFR3 | |
| SCHEMBL374251 | 0.74 | LCK (0.69) | LCKFGFR1CYP3A4FGFR3CYP2C19 | |
| SCHEMBL374686 | 0.74 | LCK (0.72) | LCKEGFRCYP3A4FGFR3CYP2C19 | |
| SCHEMBL374147 | 0.73 | LCK (1.00) | LCKCYP3A4FGFR3CYP2C19 | |
| SCHEMBL374236 | 0.72 | LCK (0.79) | LCKCYP3A4FGFR3CYP2C19 | |
| SCHEMBL374185 | 0.72 | LCK (0.76) | LCKEGFRERBB3CYP3A4FGFR3 | |
| SCHEMBL374125 | 0.71 | LCK (0.76) | LCKCYP3A4FGFR3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | LCK 120/4885EGFR 397/4885ERBB3 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.